JW Bioscience has signed a non-exclusive agreement to transfer its patented technology of multiple-biomarker complement factor b (CFB) and carbohydrate antigen 19-9 (CA19-9) to Sweden's Immunovia AB.

JW Bioscience CEO Hahm Eun-kyung (left) signed a non-exclusive licensing agreement with Immunovia AB CEO Patrik Dahlen to transfer its technology of diagnostic kit for detecting pancreatic cancer using biomarkers CFB and CA19-9.
JW Bioscience CEO Hahm Eun-kyung (left) signed a non-exclusive licensing agreement with Immunovia AB CEO Patrik Dahlen to transfer its technology of diagnostic kit for detecting pancreatic cancer using biomarkers CFB and CA19-9.

The company developed the technology to detect pancreatic cancer early with a diagnostic kit using the biomarkers CFB and CA19-9. It received patents in Korea, the U.S., China, Japan, and 21 European countries.

Under the accord, Immunovia AB has secured the rights to commercialize products using CFB and CA19-9 globally. With the recent technology transfer deal, JW Bioscience expects to have an advanced position in the global in-vitro diagnostic market.

JW Bioscience is also developing its diagnostic kit using CFB and CA19-9 for detecting pancreatic cancer in its early stages.

The company believes the recently transferred technology would diagnose pancreatic cancers that could be cured if caught in early stages with a minimal amount of serum sample collected from patients, meeting the needs as a novel method to increase the survival rate.

"We are delighted to enter into the agreement that further secures and validates our biomarker discovery approach," Immunovia AB CEO Patrik Dahlen said. "With the agreement, Immunovia AB and JW Bioscience will also evaluate possibilities for commercial collaboration to enable early detection of pancreatic cancer in the Korean market."

Immunovia recently developed and is exclusively selling the world's first laboratory-developed test (LDT) service for early diagnosis of pancreatic cancer in the U.S.

JW Bioscience CEO Hahm Eun-kyung said, "The recent license agreement with Immunovia AB is an important milestone for our intellectual property position and the recognition of superior technology in the global market.

The collaboration with Immunovia will further strengthen JW Bioscience's technology's commercial and technological competitiveness, Hahm added.

Copyright © KBR Unauthorized reproduction, redistribution prohibited